ProM1 MHC Class I Monomers, biotin labeled

enabling specialist assays for defined

MHC Class I peptide target interactions

Figure: ProM1 Monomer

Best in Class MHC Class I Monomers

ProM1 Class I MHC Monomers are provided already biotin labeled and can be readily adapted to implement specialist solid or solution phase immunoassays or for measuring interactions of predefined MHC Class I-peptide complexes with ligands such as monoclonal antibodies, recombinant T cell receptors, or other binding scaffolds, e.g. for use in screening of novel antigen-specific CAR T cell antigen receptors.

ProM1 MHC Monomers are made by ProImmune’s experienced team who have been providing superior MHC reagents for more than 18 years now, including our world-leading Pro5® MHC Class I Pentamers.

ProImmune provides ProM1 Class I MHC Monomers  with responsive, expert technical support and customer service. Contrary to ordering class I monomers from in-house or non-commercial facilities, customers do not need to apply and wait for reagents or supply any peptide. ProM1 Class I MHC Monomers are delivered quickly with stringent quality control and low batch-to-batch variability. As such, ProM1 Class I MHC Monomers complement ProImmune’s existing Pro5® Class I Pentamer technology for detecting antigen-specific CD8+ T cells.

 

Available Quantities

35ug, 100ug; please contact us for larger quantities

Catalog ProM1™ Class I MHC Monomers

Catalog ProM1™ Monomers are available within 1-2 weeks of placing an order.

DISEASEALLELEPEPTIDE CODEPEPTIDE SEQUENCEEPITOPE ORIGIN
AAVA*01:01886SADNNNSEYAAV VP1 492-500
AdenovirusA*01:01686TDLGQNLLYAdenovirus 5 Hexon 886-894
CancerA*01:013623DSDPDSFQDYTyr A1a 454-463
CancerA*01:013624EADPIGHLYMAGEA3
CancerA*01:0129EADPTGHSYMAGE-A1 161-169
CancerA*01:013626EVDPASNTYMAGE-A4 169-177
CancerA*01:0130EVDPIGHLYMAGE-A3 168-176
CancerA*01:013627HSTNGVTRIYPSMA
CancerA*01:013628ILDTAGREEYN-ras 55-64
CancerA*01:01467KCDICTDEYTyrosinase 243-251
CancerA*01:01307KSDICTDEYTyrosinase 243-251 (244S)
CancerA*01:013622LTDDRLFTCYPLEKHM2
CancerA*01:013630LVDVMPWLQYCytochrome P450 240-249
CancerA*01:011542QSLEIISRYMcl-1 177-185
CancerA*01:013632RSDSGQQARYAIM-2
CancerA*01:013383TLDTLTAFYMesothelin 429-437
CancerA*01:013633VTEPGTAQYMinor antigen HA-3T (Lbc oncogene 451-459)
CancerA*01:013634VYDFFVWLHYTRP-2 181-190
CancerA*01:012102YVDFREYEYYFLT3 ITD
CMVA*01:01739VTEHDTLLYHCMV pp50 245-253
CMVA*01:01266YSEHPTFTSQYHCMV pp65 363-373
COVID-19 / SARS-CoV-2A*01:014501CTDDNALAYYSARS-Cov-2 ORF1ab 4163-4172
COVID-19 / SARS-CoV-2A*01:014355FTSDYYQLYSARS-CoV-2 ORF3a 207-215 (confirmed epitope)
COVID-19 / SARS-CoV-2A*01:014690HTTDPSFLGRYSARS-CoV-2 ORF1ab 1641-1651
COVID-19 / SARS-CoV-2A*01:014726IVDTVSALVYSARS-CoV-2 ORF1ab 5781-5789
COVID-19 / SARS-CoV-2A*01:014382PTDNYITTYSARS-CoV-2 Replicase polyprotein 1ab 1621-1629 (confirmed epitope)
COVID-19 / SARS-CoV-2A*01:014381TTDPSFLGRYSARS-CoV-2 Replicase polyprotein 1ab 1637-1646 (confirmed epitope)
HBVA*01:013939LLDTASALYCore 30-38
HCVA*01:011066ATDALMTGFHCV NS3 1436-1444
HCVA*01:01740ATDALMTGYHCV NS3 1435-1443
InfluenzaA*01:0176CTELKLSDYInfluenza A (PR8) NP 44-52
InfluenzaA*01:01540VSDGGPNLYInfluenza A PB1 591-599
Minor Histocompatibility AntigenA*01:01652IVDCLTEMYDRRFY 1521-1529
AutoimmunityA*02:012259ALWGPDPAAAProinsulin precursor 15-24
AutoImmunityA*02:01851HLVEALYLVInsulin B chain 10-18
AutoImmunityA*02:01151KLQVFLIVLT1D Diabetes human prepro islet amyloid polypeptide ppIAPP 5-13
AutoImmunityA*02:01954LNIDLLWSVT1D Diabetes IGRP 228-236
AutoimmunityA*02:012382MVWESGCTVIA-2 797-805
AutoimmunityA*02:01969RLLPLLALLInsulin Precursor 76-90
AutoImmunityA*02:01470SLSRFSWGAMyelin basic protein 110-118
AutoimmunityA*02:013394VIVMLTPLVIA-2 805-813
AutoimmunityA*02:011904VLFGLGFAIT1D Diabetes IGRP 265-273
AutoImmunityA*02:01393VMNILLQYVGAD65 114-123
AutoimmunityA*02:013342YTCPLCRAPVSSA SS-56 55-64
BK virusA*02:011516AITEVECFLVP1 44-52
BK virusA*02:013903CLLPKMDSVlarge T antigen 398-406
BK virusA*02:011783FLHCIVFNVlarge T antigen 410-418
BK virusA*02:013781LLMWEAVTVVP1 108-116
CancerA*02:012291AILALLPALProstate Stem Cell Antigen (PSCA) 105-133
CancerA*02:013636AILALLPALLPSCA
CancerA*02:013420AIQDLCLAVNPM1
CancerA*02:013422AIQDLCVAVNPM1
CancerA*02:01543ALCNTDSPLiLR1
CancerA*02:01599ALDVYNGLLProstatic acid phosphatase precursor (PAP) 299-307
CancerA*02:01600ALFDIESKVPSM P2 (prostate)
CancerA*02:013718ALGGHPLLGVDickkopf-related protein 1 20-29
CancerA*02:013638ALIHHNTHLHER2 466-474
CancerA*02:01550ALKDVEERVMAGE-C2 336-344
CancerA*02:013719ALLAGLVSLFGFR4 676-684
CancerA*02:012860ALLPAVPSLWilms Tumor Protein 83-91
CancerA*02:011920ALLTSRLRFITelomerase Reverse Transcriptase (hTRT) 615-624
CancerA*02:013720ALLTYMIAHIThymidylate synthase 231-240
CancerA*02:013721ALMDKSLHVMART-1 56-64
CancerA*02:011778ALMEQQHYVITGB8 662-670
CancerA*02:013343ALNVYNGLLACPP 299-307
CancerA*02:011508ALPFGFILVIL13R 345-353
CancerA*02:013722ALPPPLMLLHeparanase 8-16
CancerA*02:0186ALQPGTALLProstate Stem Cell Antigen (PSCA) 14-22
CancerA*02:013344ALSPVPPVVBcl-2 85-93
CancerA*02:013723ALSVMGVYVMAGEA9 223-231
CancerA*02:013423ALTPVVVTLcyclin-dependent kinase 4 170-178
CancerA*02:013345ALVCYGPGIFAP alpha 463-471
CancerA*02:013724ALVEFEDVLhnRNP L 140-148
CancerA*02:013725ALWPWLLMARNF43 11-19
CancerA*02:013346ALWPWLLMATRNF43 11-20
CancerA*02:013347ALYLMELTMCB9L2
CancerA*02:01527ALYVDSLFFLPRAME PRA 300-309
CancerA*02:013726AMLGTHTMEVMelanocyte-specific secreted glycoprotein 184-193
CancerA*02:012569AMVGAVLTATyrosinase 482-190
CancerA*02:012582ATVGIMIGVCEACAM5 687-695
CancerA*02:013728AVIGALLAVMelanocyte-specific secreted glycoprotein 20-28
CancerA*02:011130AVLPLLELVMCL-1 139-147
CancerA*02:013350CLPSPSTPVBMI1 271-279
CancerA*02:011779CLTSTVQLVHER-2/neu 789-797
CancerA*02:013730CLYGNVEKVhnRNP L 404-412
CancerA*02:013641CMHLLLEAVMG50 624-632
CancerA*02:013731DLIFGLNALHeparanase 185-193
CancerA*02:0182ELAGIGILTVMelanA / MART 26-35
CancerA*02:013732ELFQDLSQLETV5 54-53
CancerA*02:013352ELSDSLGPVPASD1 695-703
CancerA*02:013733FAWERVRGLCyclin-dependent kinase inhibitor 1 97-105
CancerA*02:013734FIASNGVKLVACTN4 118-127 (K5N)
CancerA*02:012083FLAEDALNTVEpithelial Discoidin Domain Receptor 1 (EDDR1) 867-876
CancerA*02:011302FLAKLNNTVHCA587 317-325
CancerA*02:013735FLALIICNATubulin beta 4 283-291
CancerA*02:013736FLDEFMEGVMalic enzyme 224-232
CancerA*02:012282FLDPRPLTVCYP190
CancerA*02:013355FLFLRNFSLTARP(V28L)27-35
CancerA*02:011013FLGYLILGVProstatic Acid Phosphatase-3 (PAP-3)
CancerA*02:013643FLIIWQNTMFSP26
CancerA*02:013356FLPSPLFFFLTARP(P5L) 5-13
CancerA*02:013644FLPWHRLFLLTyrosinase 207-216
CancerA*02:01998FLTGNQLAV5T4 97-105
CancerA*02:01404FLTPKKLQCVProstate Specific Antigen-1 (PSA-1) 141-150
CancerA*02:0134FLWGPRALVMAGEA3 271-279
CancerA*02:012079FLYDDNQRVTopoisomerase II-alpha-b 828-836
CancerA*02:01306FLYTLLREVSTEAP 86-94
CancerA*02:01163FMNKFIYEIHuman alfa fetoprotein 158-166
CancerA*02:01813FVGEFFTDVGPC3 144-152 (overexpressed in hepatocellular carcinoma)
CancerA*02:013647FVWLHYYSVTRP2 185-193(L)
CancerA*02:011386GLAPPQHLIRVp53 187-197
CancerA*02:013648GLFGDIYLACSNK1A1 26-34
CancerA*02:013649GLFGDIYLAICSNK1A1 26-35
CancerA*02:013357GLFKCGIAVFAP 639-647
CancerA*02:013358GLIQLVEGVTRAG-3 4-12
CancerA*02:011786GLLGASVLGLTelomerase Reverse Transcriptase (hTRT) 674-683
CancerA*02:01560GLMEEMSALHuman Mena protein (overexpressed in breast cancer)
CancerA*02:012236GLMKYIGEVTRPM8 187-195
CancerA*02:012293GLQHWVPELBA46 (Lactadherin) 97-106
CancerA*02:012778GLSNLTHVLPRAME (432-440)
CancerA*02:01164GLSPNLNRFLAlpha-fetoprotein isoform 2 167-176
CancerA*02:01389GLYDGMEHLMAGEA-10 254-262
CancerA*02:012669GVLLWEIFSLVEGFR1 28-37
CancerA*02:01125GVLVGVALICarcinogenic Embryonic Antigen (CEA) 694-702
CancerA*02:012294GVRGRVEEIBCR-ABL
CancerA*02:01575GVYDGREHTVMAGE-A4 230-239
CancerA*02:01249HLSTAFARVG250 (renal cell carcinoma) 217-225
CancerA*02:01226HLYQGCQVVReceptor tyrosine-protein kinase erbB-2 48-56
CancerA*02:0185ILAKFLHWLTelomerase 540-548
CancerA*02:013361ILGVLTSLVDLK1 309-317
CancerA*02:01811ILHDGAYSLHER-2 434-443
CancerA*02:01210ILHNGAYSLHER-2/neu 435-443
CancerA*02:013654ILLRDAGLVTRAG-3L 58-66
CancerA*02:013655ILLVVVLGVReceptor tyrosine-protein kinase erbB-2 707-715
CancerA*02:01329ILLWQPIPVProstatic Acid Phosphatase-3 (PAP-3) 135-143
CancerA*02:013656ILNAMIAKIHAUS3 154-162
CancerA*02:01468ILSLELMKLReceptor for hyaluronic acid-mediated motility (RHAMM) 165-173
CancerA*02:0146IMDQVPFSVgp100 (pmel17) 209-217
CancerA*02:012296ITDQVPFSVgp100 (pmel) 209-217
CancerA*02:011246KASEKIFYVSSX2 41-49
CancerA*02:013658KASEYLQLVMAGEA2 153-161
CancerA*02:01214KIFGSLAFLHER-2/neu 369-377
CancerA*02:013659KIWEELSVLMAGEA3 220-228
CancerA*02:012297KLCPVQLWVp53 139-147
CancerA*02:01646KLFGTSGQKTEGF-R-479 350-359
CancerA*02:013660KLIDRTE(S)LLSP1 325-333
CancerA*02:013416KLMSSNSTDLHSP105 234-243
CancerA*02:01405KLQCVDLHVProstate Specific Antigen 146-154
CancerA*02:01859KLQDASAEVHM1.24-aa 126-134
CancerA*02:013661KLTGDENFTITyrosinase precursor 224-233
CancerA*02:01655KLVVVGADGVKRAS G12D (5-14)
CancerA*02:01752KLVVVGAVGVKRAS G12V (5-14)
CancerA*02:0157KTWGQYWQVgp100 (pmel17) 154-162
CancerA*02:012298KVAEELVHFLMAGEA3 112-120 (alternative version)
CancerA*02:01302KVAELVHFLMAGEA3 112-120
CancerA*02:013006KVDELAHFLMelanoma-associated antigen 4 (MAGE4) 113-121
CancerA*02:013080KVLEHVVRVMelanoma-associated antigen 4 (MAGE4) 286-294
CancerA*02:01171KVLEYVIKVMAGEA1 278-286
CancerA*02:011421KVVEFLAMLMAGE-C1 1083-1091
CancerA*02:01810LIAHNQVRQVHER-2/neu (85-94)
CancerA*02:01628LLAARAIVAIiLR1 59-68
CancerA*02:013662LLCYSCKAQVPSCA 17-26
CancerA*02:01221LLDVAPLSLHSP1A 461-469
CancerA*02:011303LLFGLALIEVMAGE-C2 191-200
CancerA*02:01516LLGATCMFVCyclinD 101-109
CancerA*02:01205LLGRNSFEVp53 264-272
CancerA*02:01690LLHETDSAVPSMA/PSM-P1 4-12
CancerA*02:011007LLLAGLFSLFibromodulin 7-15
CancerA*02:013666LLLEAVPAVMG50 69-77
CancerA*02:01841LLLIWFRPVBKV Ltag 579-587
CancerA*02:01220LLLLDVAPLHSP1A 459-467
CancerA*02:01208LLLLTVLTVMUC-1 12-20
CancerA*02:01381LLLTVLTVVTumor Mucin Antigen 13-21
CancerA*02:013668LLNQLQVNLMucin2 467-475
CancerA*02:013669LLRDAGLVKMTRAP 59-68
CancerA*02:013670LLRRYNVAKVSOX11 266-275
CancerA*02:013671LLSHGAVIEVAnkyrin NYBR1 158-167
CancerA*02:013363LLVPTCVFLV691-700
CancerA*02:012793LMAQEALAFLCAMEL 2-11
CancerA*02:01391LMLGEFLKLSurvivin 96-104
CancerA*02:011464LTLGEFLKLSurvivin-3A 96-104
CancerA*02:013673LVFGIELMEVMAGEA3 160-169
CancerA*02:013674LVFGIEVVEVMAGEA12 160-169
CancerA*02:013365MLAVFLPIVSTEAP 292-300 (293L)
CancerA*02:013675MLWGWREHVMucin2 645-653
CancerA*02:013366NLFETPVEA194-202
CancerA*02:01480PLFDFSWLSLBcl-2 208-217
CancerA*02:01162PLFQVPEPVAlpha-fetoprotein isoform 1 137-145
CancerA*02:013678PLQPEQLQVReceptor tyrosine-protein kinase erbB-2 437-445
CancerA*02:01662PLTSIISAVReceptor tyrosine-protein kinase erbB-2 728-736
CancerA*02:01338QLCPICRAPVLivin/ML-IAP280 175-184
CancerA*02:01780QLFEELQELHeme oxygenase-1 212-220
CancerA*02:013368QLGEQCWTVPSCA 44-51 (51A)
CancerA*02:011908QLLDGFMITLPASD1 39-48
CancerA*02:013421QLLIKAVNLMPP11
CancerA*02:013680QLMAFNHLIPAX3/FKHR 135-143
CancerA*02:013681QLMPYGCLLReceptor tyrosine-protein kinase erbB-2 845-853
CancerA*02:013371RLAEYQAYISART3 309-317
CancerA*02:01997RLARLALVLTrophoblast glycoprotein 17-25
CancerA*02:01787RLASFYDWPLBIR7 90-99
CancerA*02:013684RLGPTLMCLMG50 1244-1252
CancerA*02:01212RLLQETELVHER-2/neu 689-697
CancerA*02:01960RLMNDMTAVHSP105 128-136
CancerA*02:01337RLQEERTCKVBIR
CancerA*02:013436RLQGISPKISSX2 103-111
CancerA*02:011937RLSSCVPVA131-139
CancerA*02:013687RLTRFLSRVCyclinD 228-236
CancerA*02:01117RLVDDFLLVTelomerase Reverse Transcriptase 865-873
CancerA*02:01884RLWQELSDIcircadian clock protein PASD1 691-700
CancerA*02:01202ARMFPNAPYLWT-1 126-134 (Wilms tumor)
CancerA*02:01654RMPEAAPPVp53 65-73
CancerA*02:013688RTF(S)PTYGLDesmuslin 426-434
CancerA*02:012988RVA(PHOSPHO-S)PTSGVInsulin receptor substrate-2 1097-1105
CancerA*02:012990RVASPTSGVIRS-2 1097-1105
CancerA*02:013374SIDWFMVTVp31-39
CancerA*02:013689SILLRDAGLTRAP 57-65
CancerA*02:013375SILLRDAGLVTRAG-3 57-66
CancerA*02:013691SLADEAEVYLGAS7 Neoepitope
CancerA*02:01637SLAMLDLLHVMutant anaplastic lymphoma kinase 1220-1229
CancerA*02:013693SLDDYNHLVL-dopachrome tautomerase 288-296
CancerA*02:01457SLEENIVILRHAMM 275-283
CancerA*02:013377SLFEPPPPGPSMA 85-93
CancerA*02:011056SLFLGILSVCD20 188-196 (B cell malignancies)
CancerA*02:01452SLGEQQYSVWT1 187-195
CancerA*02:01774SLLFLLFSLMesothelin 20-28
CancerA*02:0149SLLMWITQCNY-ESO-1 157-165 (9C)
CancerA*02:01390SLLMWITQVNY-ESO-1 157-165
CancerA*02:01861SLLQHLIGLPRAME 425-433
CancerA*02:012299SLPPPGTRVp53 149-157
CancerA*02:011181SLSEKTVLLCD59 glycoprotein precursor 106-114
CancerA*02:01958SLVDVMPWLCytochrome p450 1B1 239-248
CancerA*02:013695SLYKFSPFPLO-linked N-acetylglucosamine transferase FSP06
CancerA*02:01860SLYSFPEPEAPRAME
CancerA*02:013417SLYSYFQKVMembrane-associated transporter protein
CancerA*02:013696SMTR(S)PPRVSFRS2B 241-249
CancerA*02:013379SQADALKYVEZH2 729-737
CancerA*02:013418STLCQVEPVMPP11
CancerA*02:011509TLADFDPRVEphA2
CancerA*02:01408TLAPATEPAMucin 79-87
CancerA*02:013698TLEEITGYLReceptor tyrosine-protein kinase erbB-2 448-456
CancerA*02:013699TLHCDCEILMG50 210-218
CancerA*02:01915TLPGYPPHVPAX-5 311-319
CancerA*02:012371TLQDIVYKLBMI1 74-82
CancerA*02:01561TMNGSKSPVhMena 502-510
CancerA*02:01862VIFDFLHCIBKV Ltag 406-414
CancerA*02:011403VIMPCSWWVChondromodulin-I 319-327
CancerA*02:0197VISNDVCAQVProstate Specific Antigen-1 (PSA-1) 154-163
CancerA*02:01689VLAGGFFLLPSMA 27-38
CancerA*02:01304VLAGVGFFIEPHA2 550-558
CancerA*02:01893VLDFAPPGAWT1
CancerA*02:01781VLDGLDVLLPRAME 100-108
CancerA*02:013702VLEPPGARDVBIR 7 230-239
CancerA*02:01345VLGEAWRDQVTRAP 45-54
CancerA*02:013704VLLALLMAGLProstate stem cell antigen 4-13
CancerA*02:01773VLPLTVAEVMesothelin 530-538
CancerA*02:01250VLQELNVTVLeukocyte Proteinase-3 (Wegener's autoantigen) 169-177
CancerA*02:013419VLQMKEEDViLR1
CancerA*02:013705VLSVNVPDVMG50 625-633
CancerA*02:013706VLVKSPNHVReceptor tyrosine-protein kinase erbB-4 890-898
CancerA*02:01157VLYRYGSFSVgp100 (pmel17) 476-485
CancerA*02:01693VMAGVGSPYVReceptor tyrosine-protein kinase erbB-2 819-828
CancerA*02:013708VMIG(S)PKKVTensin3 1558-1566
CancerA*02:013709VVLGVVFGIReceptor tyrosine-protein kinase erbB-2 743-751
CancerA*02:013710WLPKILGEVMG50 1051-1059
CancerA*02:013711WLQYFPNPVCytochrome P450 246-254
CancerA*02:013386WLSLKTLLSLBcl-2 214-223
CancerA*02:012457YAIDLPVSVL-dopachrome tautomerase 488-496
CancerA*02:0158YLEPGPVTAgp100
CancerA*02:0147YLEPGPVTVgp100 (pmel) 280-288 (288V)
CancerA*02:01394YLFFYRKSVmTERT 572-580
CancerA*02:012300YLGSYGFRLp53 103-111
CancerA*02:012081YLIELIDRVTACE 250-258
CancerA*02:011239YLISGDSPVCD33 65-73 (1Y2L)
CancerA*02:013713YLLDLSTNHLFibromodulin 7-15
CancerA*02:01594YLNDHLEPWIBcl-X 173-182
CancerA*02:012194YLNPSVDSVEWS-FLI-1 oncogene
CancerA*02:013387YLNRHLHTWIBCL-2 180-189
CancerA*02:01645YLNTVQPTCVEGF-R 1138-1147
CancerA*02:01922YLQHNEIQEVFibromodulin 206-215
CancerA*02:012301YLQLVFGIEVMAGEA2 157-166
CancerA*02:01447YLQVNSLQTVTelomerase Reverse Transcriptase (hTRT) 988-997
CancerA*02:013388YLQWIEFSIProminin1 744-752
CancerA*02:0148YLSGADLNLCarcinoembryonic antigen (CEA)-derived peptide CAP1-6D
CancerA*02:0175YLSGANLNLCarcinogenic Embryonic Antigen (CEA) 571-579
CancerA*02:011910YLVGNVCILPASD1 168-176
CancerA*02:013715YLWWVNNQSLCEA 176-185
CancerA*02:013389YLYQWLGAPVOsteocalcin 51-60
CancerA*02:011201YMCSFLFNLEwing Tumor EZH2 666-674
CancerA*02:0161YMDGTMSQVTyrosinase 369-377 (371D)
CancerA*02:01921YMEHNNVYTVFibromodulin 250-259
CancerA*02:01464YMNGTMSQVTyrosinase 368-376
CancerA*02:012649YVDPVITSIHepatocyte growth factor receptor 673-681
ChlamydiaA*02:01335NMFTPYIGVMOMP precursor 283-291
ChlamydiaA*02:01334RLNMFTPYIChlamydia trachomatis MOMP 258-266
CMVA*02:012205MLNIPSINVpp65 120-128
CMVA*02:018NLVPMVATVHCMV pp65 495-504
CMVA*02:011598VLAELVKQIHCMV IE1 81-89
CMVA*02:01144VLEETSVMLHCMV IE1 316-324 (UL123)
COVID-19 / SARS-CoV-2A*02:014322ALNTLVKQLSARS-CoV Spike glycoprotein precursor 940-948 (conserved in SARS-CoV-2)
COVID-19 / SARS-CoV-2A*02:014321FIAGLIAIVSARS-CoV-2 Spike glycoprotein 1220-1228 (confirmed epitope)
COVID-19 / SARS-CoV-2A*02:014340KIADYNYKLSARS-CoV-2 Spike glycoprotein 417-425
COVID-19 / SARS-CoV-2A*02:014418KLWAQCVQLSARS-CoV-2 ORF1ab 3886-3894 (confirmed epitope)
COVID-19 / SARS-CoV-2A*02:014323LITGRLQSLSARS-CoV-2 Spike glycoprotein 996-1004 (confirmed epitope)
COVID-19 / SARS-CoV-2A*02:014320LLLDRLNQLSARS-CoV Nucleocapsid protein 223-231 (conserved in SARS-CoV-2)
COVID-19 / SARS-CoV-2A*02:014342LLYDANYFLSARS-CoV-2 ORF3a 139-147 (confirmed epitope)
COVID-19 / SARS-CoV-2A*02:014324NLNESLIDLSARS-CoV Spike glycoprotein precursor 1174-1182 (conserved in SARS-Cov-2)
COVID-19 / SARS-CoV-2A*02:014358RLQSLQTYVSARS-CoV-2 Spike glycoprotein 1000-1008 (confirmed subdominant epitope)
COVID-19 / SARS-CoV-2A*02:014725TLVPQEHYVSARS-CoV-2 ORF1ab 5563-5571
COVID-19 / SARS-CoV-2A*02:014326VLNDILSRLSARS-CoV Spike glycoprotein precursor 958-966 (conserved in SARS-Cov-2)
COVID-19 / SARS-CoV-2A*02:014339YLQPRTFLLSARS-Cov-2 Spike glycoprotein 269-277 (confirmed epitope)
DengueA*02:013918AIKRGLRTLDengue NS3 112-120
DengueA*02:013914ILIRTGLLVIDengue NS2b 97-106
DengueA*02:013910KLAEAIFKLDengue NS5 563-571
DengueA*02:013923LLLGLMILLDengue NS4a 56-64
DengueA*02:012929TLYAVATTIDengue NS4b 40-48
DengueA*02:013928VLLLVTHYADengue NS4b 111-119
EBVA*02:0142CLGGLLTMVEBV LMP-2 426-434
EBVA*02:012292FLDKGTYTLEBV BALF-4 276-284
EBVA*02:01666FLYALALLLEBV LMP-2 356-364
EBVA*02:013462FMVFLQTHIEBV EBNA-1 (562-570)
EBVA*02:011GLCTLVAMLEBV BMLF-1 259-267
EBVA*02:011616LLDFVRFMGVEBV EBNA-3C 284-293
EBVA*02:01872TLDYKPLSVEBV BMRF1 208-216
EBVA*02:01409YLLEMLWRLEBV LMP-1 125-133
EBVA*02:01410YLQQNWWTLEBV LMP1 159-167
EBVA*02:01462YVLDHLIVVEBV BRLF1 109-117
HAVA*02:012257LLYNCCYHVHepatitis A Virus polyprotein 2027-2034
HBVA*02:013934ELMTLATWVcore protein 64-72
HBVA*02:0132FLLSLGIHLHBV polymerase 573-581
HBVA*02:0127FLLTRILTIHBV envelope 183-191
HBVA*02:01283FLPSDFFPSIHBV core 18-27 (subtype ADR4)
HBVA*02:0123FLPSDFFPSVHBV core antigen 18-27
HBVA*02:0128GLSPTVWLSVHBV surface antigen 185-194
HBVA*02:01778GLSRYVARLHBV Pol 455-463
HBVA*02:012829KLHLYSHPIPol 502-510
HBVA*02:01500VLHKRTLGLX 92-100
HBVA*02:0131WLSLLVPFVHBV surface antigen 172-181
HBVA*02:011194YMDDVVLGAPolymerase 548-556
HCVA*02:0137ALYDVVTKLHCV NS5b 2594-2602
HCVA*02:013CINGVCWTVHCV NS3 1073-1081
HCVA*02:01858CVNGVCWTVHCV NS3 1073-1081
HCVA*02:012DLMGYIPAVHCV core 132-140
HCVA*02:01491DLMGYIPLVHCV core 132-140
HCVA*02:011094GLQDCTMLVHCV NS5B 2727-2735
HCVA*02:01242KLSGLGINAVHCV NS3 1406-1415
HCVA*02:01243KLSGLGLNAVHCV NS3 1406-1415
HCVA*02:0140KLVALGINAVHCV NS3 1406-1415
HCVA*02:01172LLFNILGGWVHCV NS4b 1807-1816
HCVA*02:0136VLSDFKTWLHCV NS5a 1987-1995
HCVA*02:014YLLPRRGPRLHCV core 35-44
HIV/SIVA*02:011240ALVEMGHHAHIV Vpu 66-74
HIV/SIVA*02:011147FLGKIWPSGag 433-440
HIV/SIVA*02:01430GLADQLIHLHIV-1 Vif 101-109
HIV/SIVA*02:0184ILKEPVHGVHIV-1 RT 476-484
HIV/SIVA*02:01246KLTPLCVTLHIV-1 env gp120 90-98
HIV/SIVA*02:01799LTFGWCFKLHIV-1 Nef 137-145
HIV/SIVA*02:011244NVWATHACVHIV Env gp 67-7
HIV/SIVA*02:011241RTLNAWVKVHIV Gag 150-158
HIV/SIVA*02:013401SLFNTVATLHIV gag 77-85
HIV/SIVA*02:011537SLLNATAIAVHIV env 816-825
HIV/SIVA*02:013402SLVKHHMYIHIV Vif 23-31
HIV/SIVA*02:0110SLYNTVATLHIV-1 gag p17 76-84
HIV/SIVA*02:01174TLNAWVKVVHIV-1 gag p24 19-27
HIV/SIVA*02:013403VIYHYVDDLHIV Pol
HPVA*02:01658KLPQLCTELHPV 16 E6 18-26
HPVA*02:012312MLDLQPETTHPV 16 E7 12-20
HPVA*02:012103YMLDLQPETHPV E7 11-19
HPVA*02:0195YMLDLQPETTHPV 16 E7 11-20
HSVA*02:011153QLFNHTMFINon-muscle Myosin 478-486
HSVA*02:013406QMARLAWEA1116-1124
HSVA*02:011152VLMIKALELNon muscle Myosin-9 741-749
HTLVA*02:012309AVLDGLLSLHTLV bZIP factor 42-50
HTLVA*02:013408GLLSLEEELbZIP factor 26-34
HTLVA*02:01200LLFGYPVYVHuman T-cell lymphotropic virus-1 (HTLV-1) tax 11-19
InfluenzaA*02:017GILGFVFTLInfluenza A MP 58-66
InfluenzaA*02:012295ILGFVFTLTVInfluenza A MP 59-68
InfluenzaA*02:013409KLGEFYNQMMFlu BNP 85-94 (Influenza B)
JC VirusA*02:01611ILMWEAVTLVP1 100-108
JC VirusA*02:01610SITEVECFLVP1 36-44
LCMVA*02:012308ALPHIIDEVLCMV envelope gp 10-18
LCMVA*02:013411SLNQTVHSLNP 69-77
LCMVA*02:012310YLVSIFLHLLCMV envelope gp 447-455
MalariaA*02:01314YLNKIQNSLPlasmodium falciparum CSP 334-342
Minor Histocompatibility AntigenA*02:01175FIDSYICQVmiHAg H-Y (human SMCY) 311-319
Minor Histocompatibility AntigenA*02:01581RTLDKVLEVmiHAg HA-8
Minor Histocompatibility AntigenA*02:01473VLHDDLLEAMinor Histocompatibility Antigen HA-1 137-145
Minor Histocompatibility AntigenA*02:01395YIGEVLVSVHA-2
NegativeA*02:01N01NEGATIVENegative Control
NorovirusA*02:013214TMFPHIIVDVNorovirus VP1 139-148
OtherA*02:013041ILEDIVLTLStreptococcus pyogenes Cas9 615-623
OtherA*02:01133LLDVPTAAVInterferon gamma inducible protein (GILT) 30 27-35
OtherA*02:01366LMWYELSKIKSHVF-8 gB.492-500
OtherA*02:01353RILGAVAKVVinculin 822-830
OtherA*02:01370TIHDIILECVAlpha papillomavirus 9 E6 Protein (22-31)
RSVA*02:01801KMLKEMGEVRSV NP 137-145
TuberculosisA*02:01620AMASTEGNVESAT-6
TuberculosisA*02:01619GILTVSVAV16 kDa
TuberculosisA*02:01324GLPVEYLQVMycobacterium bovis antigen 85-A 6-14
TuberculosisA*02:01276KLIANNTRVMycobacterium bovis antigen 85-A 200-208
TuberculosisA*02:012221VLTDGNPPEV19 kDa
VacciniaA*02:01978ILDDNLYKVVaccinia virus Copenhagen Protein G5 18-26
VacciniaA*02:01703KVDDTFYYVVaccinia virus Host range protein 2 74-82
Varicella Zoster VirusA*02:01995ALWALPHAAIE62 593-601
West NileA*02:011322ATWAENIQVWest Nile virus NY-99 polyprotein precursor 3390-3398
West NileA*02:011320RLDDDGNFQLWest Nile Virus NY-99 polyprotein precursor (1452-1461)
West NileA*02:011327YTMDGEYRLWest Nile virus NY-99 polyprotein precursor 2023-2031
West Nile VirusA*02:011324SLFGQRIEVWNV nonstructural protein 4B 15-23
West Nile VirusA*02:011321SVGGVFTSVWNV envelope gp 430-438
Yellow Fever VirusA*02:012097LLWNGPMAVNS4B 214-222
CancerA*03:01118ALLAVGATKgp100 (pmel17) 17-25
CancerA*03:01264ATGFKQSSKbcr-abl 210 kD fusion protein 259-269
CancerA*03:0187KQSSKALQRbcr-abl 210 kD fusion protein 21-29
CancerA*03:013369QVLKKIAQKHMOX1 145-153
CancerA*03:013370RIAAWMATY165-173
CancerA*03:01541RISTFKNWPKSurvivin-3A 18-27 (27K)
CancerA*03:01552RLGLQVRKNKRhoC 176-185 (177L)
CancerA*03:01615RLLFFAPTRMcl-1 95-103
CMVA*03:011599KLGGALQAKHCMV IE1 184-192
COVID-19 / SARS-CoV-2A*03:014443KCYGVSPTKSARS-CoV-2 Spike glycoprotein 378-386
COVID-19 / SARS-CoV-2A*03:014724KLFAAETLKSARS-CoV-2 ORF1ab 5455-5463
COVID-19 / SARS-CoV-2A*03:014356AKTFPPTEPKSARS-CoV-2 Nucleocapsid protein 362-370 (confirmed epitope)
COVID-19 / SARS-CoV-2A*03:014679ASVYAWNRKRSARS-CoV-2 Spike glycoprotein 349-357
COVID-19 / SARS-CoV-2A*03:014691AVTNNTFTLKSARS-CoV-2 ORF1ab 808-816
DengueA*03:013913ELERAADVKDengue NS2b 52-60
DengueA*03:013929AKITAEWLWKDengue NS5 375-383
DengueA*03:013916ARIEPSWADVKDengue NS3 64-74
DengueA*03:013921ARVIDPRRCMKDengue NS3 422-431
DengueA*03:013910ARVSTVQQLTKDengue C 22-31
EBVA*03:01727RLRAEAQVKEBV EBNA 3A 603-611
EBVA*03:011838RVRAYTYSKEBV BRLF1
HCVA*03:0135RVCEKMALYHCV NS5B 2588-2596
HIV/SIVA*03:011496AIFQSSMTKHIV pol 325-333
HIV/SIVA*03:01109QVPLRPMTYKHIV-1 nef 73-82
HIV/SIVA*03:01194RLRPGGKKKHIV-1 gag p17 19-27
HPVA*03:012064KLCLRFLSKHPV 33 E6 64-72
InfluenzaA*03:0177ILRGSVAHKInfluenza A (PR8) NP 265-274
CancerA*11:01785VVGAVGVGKKRAS G12V (8-16)
CancerA*11:013070VVVGADGVGKKRAS G12D (7-16)
CancerA*11:013072VVVGAVGVGKKRAS G12V (7-16)
COVID-19 / SARS-CoV-2A*11:014356BKTFPPTEPKSARS-CoV-2 Nucleocapsid protein 362-370 (confirmed epitope)
COVID-19 / SARS-CoV-2A*11:014679BSVYAWNRKRSARS-CoV-2 Spike glycoprotein 349-357
COVID-19 / SARS-CoV-2A*11:014691BVTNNTFTLKSARS-CoV-2 ORF1ab 808-816
DengueA*11:014631ATVLMGLGKDENV 2 Polyprotein 2315-2323
DengueA*11:013459ATYGWNLVKDENV 1 NS5 2610-2618
DengueA*11:013907GTSGSPIADKDengue NS3 133-142
DengueA*11:012372GTSGSPIIDKDengue NS3 133-142
DengueA*11:014625GTSGSPIINKDENV 4 NS3 1607-1617
DengueA*11:011843GTSGSPIINRDengue NS3 serotype 3&4 133-142
DengueA*11:014624GTSGSPIVDKDENV 2 NS3 1608-1617
DengueA*11:013906GTSGSPIVDRDengue NS3 serotype 2 133-142
DengueA*11:012373GTSGSPIVNRNS3 serotype 1 133-142
DengueA*11:013929BKITAEWLWKDengue NS5 375-383
DengueA*11:014629KTFDSEYIKDENV 2 NS3 1863-1871
DengueA*11:014628KTFDSEYVKDENV 2 Polyprotein 1863-1871
DengueA*11:014630KTFDTEYQKDENV 1 NS3 1864-1872
DengueA*11:013916BRIEPSWADVKDengue NS3 64-74
DengueA*11:013921BRVIDPRRCMKDengue NS3 422-431
DengueA*11:013910BRVSTVQQLTKDengue C 22-31
DengueA*11:013460STYGWNIVKDENV 3 NS5 2607-2615
DengueA*11:013461STYGWNLVRDENV 2 NS5 2608-2616
DengueA*11:014626TIPPTAGILKDENV 2 Core 58-67
DengueA*11:014627TTLSRTSKKDENV 2 NS2a 1336-1344
EBVA*11:01639ATIGTAMYKEBV BRLF1 134-142
EBVA*11:01726AVFDRKSDAKEBNA3B 399-408
EBVA*11:01199IVTDFSVIKEBV EBNA-4 416-424
EBVA*11:01508SSCSSCPLSKEBV LMP-2 340-349
EBVA*11:014183SSCSSCPLTKEBV LMP-2_EBVG 339-348
HBVA*11:013941STLPETTVVRRCore 141-151
HBVA*11:012659YVNTNMGLKCore 88-96
HBVA*11:01377YVNVNMGLKHBV core antigen 88-96
HIV/SIVA*11:011686ACQGVGGPGHKHIV gag p24
HIV/SIVA*11:011486AVDLSHFLKHIV nef 84-92
HPVA*11:012067NTLEQTVKKHPV 33E6 86-94
InfluenzaA*11:011722KSMREEYRKInfluenza A MP2 70-78
InfluenzaA*11:011720RMVLASTTAKInfluenza A MP1 178-187
InfluenzaA*11:011513SIIPSGPLKInfluenza A MP 13-21
AdenovirusA*24:02684TYFSLNNKFAdenovirus 5 Hexon 37-45
CancerA*24:02230AFLPWHRLFTyrosinase 188-196
CancerA*24:022302AYACNTSTLSurvivin 80-88
CancerA*24:022303CYASGWGSIProstate Specific Antigen-1 153-161
CancerA*24:023351DYLNEWGSRFCDH3 807-816
CancerA*24:021064DYLQYVLQIMiHA ACC1 15-23
CancerA*24:023353EYCPGGNLFMELK 87-95 (93N)
CancerA*24:02416EYLQLVFGIMAGEA2 156-164
CancerA*24:023380EYRALQLHLCA9 219-227
CancerA*24:023354EYYELFVNIDEP DC1 294-302
CancerA*24:023360GYCTQIGIFHENMT1 221-229
CancerA*24:02237IMPKAGLLIMAGE-A3
CancerA*24:023362IYTWIEDHFFOXM1 262-270
CancerA*24:023367NYQPVWLCLRNF43 721-729 (722Y)
CancerA*24:021806RYCNLEGPPILymphocyte antigen 6 complex locus K (LY6K) 177-186
CancerA*24:023372RYNAQCQETIMidkine 110-119
CancerA*24:023382SYRNEIAYLTTK protein kinase 551-559
CancerA*24:02421TFPDLESEFMAGEA3 97-105
CancerA*24:02209TYACFVSNLCarcinogenic Embryonic Antigen (CEA) 652-660
CancerA*24:02417TYLPTNASLHER-2/neu 63-71
CancerA*24:02238VYFFLPDHLgp100-intron 4 (170-178)
CancerA*24:02418VYGFVRACLTelomerase reverse transcriptase (hTRT) 461-469
CancerA*24:023384VYLRVRPLLKIF20A 67-75
CancerA*24:023385VYYNWQYLLIL13r 146-154
CMVA*24:023390AYAQKIFKICMV IE-1 248-256
CMVA*24:02414QYDPVAALFHCMV pp65 341-349
CMVA*24:02380VYALPLKMLHCMV pp65 113-121
COVID-19 / SARS-CoV-2A*24:024692NYNYLYRLFSARS-CoV-2 Spike glycoprotein 448-456
COVID-19 / SARS-CoV-2A*24:024668QYIKWPWYISARS-CoV-2 Spike glycoprotein 1205-1213
COVID-19 / SARS-CoV-2A*24:024670VYIGDPAQLSARS-CoV-2 ORF1ab 5724-5732
DengueA*24:023910QYSDRRWCFDengue NS3 557-565 (Singapore/S275/1990)
DengueA*24:024632RYLEFEALGFDENV 3 NS5 2971-2980
DengueA*24:024633TYFQRVLIFDENV 2 M 261-269
DengueA*24:024081TYGWNIVKLDENV 3 NS5 2608-2616
DengueA*24:024083TYGWNLVKLDENV 1, 4 NS5 2611-2619
DengueA*24:024082TYGWNLVRLDENV 2 NS5 2609-2617
EBVA*24:02648PYLFWLAAIEBV LMP2 131-139
EBVA*24:02420TYGPVFMCLEBV LMP-2 419-427
EBVA*24:02683TYGPVFMSLEBV LMP2 419-427
HBVA*24:02378EYLVSFGVWHBV core 117-125
HBVA*24:023935FFPSIRDLLcore protein 23-31
HBVA*24:02413KYTSFPWLLHBV polymerase 756-764
HCVA*24:02415AYSQQTRGLHCV NS3 1031-1039
HIV/SIVA*24:02419RYLKDQQLLHIV-1 gag gp41 67-75
HIV/SIVA*24:021805RYLRDQQLLHIV env
HIV/SIVA*24:023238RYPLTFGWHIV nef
HIV/SIVA*24:023099RYPLTFGWCFHIV NEF 143-152
HIV/SIVA*24:02411RYPLTFGWCYHIV-1 Nef 134-143
HPVA*24:023240VYDFAFRDLHPV16 E6
HTLVA*24:021043SFHSLHLLFHTLV Tax 301-309
CancerA*29:023397KEKYIDQEELHSP90 alpha 280-288 (Pathologic Conditions)
HIV/SIVA*29:023392LYNTVATLYHIV gag 79-86
HIV/SIVA*29:023395SFDPIPIHYHIV env 216-224
HIV/SIVA*29:023396SFNCRGEFFYHIV env 382-391
AAVB*07:02651VPQYGYLTLAAV2 372-380
AdenovirusB*07:02989KPYSGTAYNALAdenovirus Hexon 114-124
AdenovirusB*07:02685KPYSGTAYNSLAdV Hexon
BK virusB*07:022070LPLMRKAYLLT antigen 27-35
CancerB*07:023348APRGVRMAVLAGE-1 46-54
CancerB*07:022369EPR(PHOSPHO-S)PSHSMInsulin receptor substrate 2
CancerB*07:023364LPVSPRLQLCEACAM 185-193
CancerB*07:022304LPWHRLFLLTyrosinase 208-216
CancerB*07:023378SPFFLLLLLTumor Mucin antigen 7-15
CancerB*07:023239TPNQRQNVCP2X5
CMVB*07:02308RPHERNGFTVLHCMV pp65 265-275
CMVB*07:0245TPRVTGGGAMHCMV pp65 417-426
COVID-19 / SARS-CoV-2B*07:024694RARSVSPKLSARS-CoV-2 ORF7a 78-86
COVID-19 / SARS-CoV-2B*07:024351SPRWYFYYLSARS-CoV-2 Nucleocapsid protein 105-113 (confirmed epitope)
DengueB*07:023909APTRVVAAEMDengue NS3 serotype 2 222-231
EBVB*07:022305QPRAPIRPIEBV EBNA-3C 881-889
EBVB*07:0244RPPIFIRRLEBV EBNA-3A 247-255
EBVB*07:02647RPQGGSRPEFVKLEBV BMRF1 116-128
HAVB*07:022164HPRLAQRILHepatitis A Virus polyprotein 1877-1885
HBVB*07:02701LPSDFFPSVCore 19-27
HCVB*07:02845DPRRRSRNLHCV core 111-119
HCVB*07:02742GPRLGVRATHCV core 41-49
HIV/SIVB*07:02877GPGHKARVLHIV gag p24 223-231
HIV/SIVB*07:02196IPRRIRQGLHIV-1 env gp120 848-856
HIV/SIVB*07:02257TPGPGVRYPLHIV-1 nef 128-137
HPVB*07:022065KPTLKEYVLHPV 33 E7 5-13
HTLVB*07:023400LPVSCPEDLbZIP factor 10-18
InfluenzaB*07:021743QPEWFRNVLInfluenza A PB1 329-337
InfluenzaB*07:021744SPIVPSFDMInfluenza A NP 473-481
Minor Histocompatibility AntigenB*07:021113SPSVDKARAELMiHAg SMCY 1041-1051
CancerB*08:0194GFKQSSKALbcr-abl 210 kD fusion protein 19-27
CMVB*08:013391ELKRKMIYMCMV IE-1 199-207 (R/L Position 3, M/I Position 7)
CMVB*08:01127ELRRKMMYMIE1 199-207
DengueB*08:013925LEKTKKDLDengue NS4a 6-13
DengueB*08:013915RIKQKGILDengue NS3 25-32
EBVB*08:0173FLRGRAYGLEBV EBNA-3A 193-201
EBVB*08:01489QAKWRLQTLEBV EBNA3A 158-166
EBVB*08:01190RAKFKQLLEBV BZLF-1 190-197
HBVB*08:013937GLKILQLLexternal core Ag
HCVB*08:01721HSKKKCDELHCV NS3 1395-1403
HIV/SIVB*08:01879EIYKRWIIHIV p24 gag 128-135
HIV/SIVB*08:01193FLKEKGGLHIV-1 nef 90-97
HIV/SIVB*08:01195GEIYKRWIIHIV-1 gag p24 261-269
HIV/SIVB*08:011536YLKDQQLLEnv 586-593
DengueB*15:013912CLIPTAMAFDengue C 107-115
HIV/SIVB*15:011072RLRPGGKKKYHIV-1 p17 20-29
CancerB*27:05424GRFGLATEKBRAF 594-601 (600E)
CancerB*27:053359GRFGLATVKBRAF 594-601 (600V)
CancerB*27:05202BRMFPNAPYLWT-1 126-134 (Wilms tumor)
ChlamydiaB*27:053094ARKLLLDNLPqqC-like protein 70-78
ChlamydiaB*27:053945NRAKQVIKLProbable ATP-dependent Clp protease ATP-binding subunit 7-15
COVID-19 / SARS-CoV-2B*27:054354QRNAPRITFSARS-CoV-2 Nucleocapsid protein 9-17
HCVB*27:05871ARMILMTHFNS5B 2841-2849
HIV/SIVB*27:052306GRAFVTIGKHIV-1 gp100 103-111
HIV/SIVB*27:05294KRWIILGLNKHIV-1 gag p24 265-274
HIV/SIVB*27:05874KRWIIMGLNKHIV-1 Gag p24 263-272
InfluenzaB*27:05463SRYWAIRTRInfluenza A NP 383-391
AdenovirusB*35:011346IPYLDGTFYAdV Hexon
CancerB*35:012307MPFATPMEANY-ESO-1 94-102
CMVB*35:01114IPSINVHHYHCMV pp65 123-131
DengueB*35:013908TPEGIIPTLDengue NS3 500-508
EBVB*35:01399EPLPQGQLTAYEBV BZLF-1 54-64
EBVB*35:013033HPVAEADYFEYEBV EBNA-1 407-417(4A)
EBVB*35:01107YPLHEQHGMEBV EBNA-3A 458-466
HCVB*35:01942CPNSSIVYHCV E1 207-214
HCVB*35:01565HPNIEEVALHCV NS3 1359-1367
HIV/SIVB*35:01255NPDIVIYQYHIV-1 HIV-1 RT 328-336
HIV/SIVB*35:011211VPLDEDFRKYHIV-1 HIV-1 RT 273-282
COVID-19 / SARS-CoV-2B*40:014328MEVTPSGTWLSARS-CoV-2 Nucleocapsid protein 322-330 (confirmed epitope)
DengueB*40:013924GEARKTFVELDengue NS3 528-537
EBVB*40:01692IEDPPFNSLEBV LMP2 200-208
HCVB*40:01939REISVPAEILHCV NS5a 2266-2275
HIV/SIVB*40:01840KEKGGLEGLHIV-1 Nef 92-100
OtherE*01:01712VMAPRTLILHLA-C leader sequence peptide
OtherE*01:012355VMAPRTLVLHLA-A leader sequence peptide
AdenovirusH-2Db2206SGPSNTPPEIAd5 E1A 234-243
AutoimmunityH-2Db1107RSPFSRVVHLMOG Precursor 69-78
CancerH-2Db695Abu-Abu-L-Abu-LTVFLMoloney murine sarcoma virus (MoMSV) GagL 85-93
CancerH-2Db2755AQLANDVVLMC-38
CancerH-2Db3349ASFRNLTHLTPBG 258-266
CancerH-2Db2695ASMTNMELMMC-38 Adpgk neoantigen
CancerH-2Db1731ATFKNWPFLMurine Survivin 20-28
CancerH-2Db231CMTWNQMNLWT1 235-243
CancerH-2Db2199FSNSTNDILIVEGFR2/KDR fragment 1 614-624
CancerH-2Db559HCIRNKSVIPSA 65-73
CancerH-2Db1780HCIRNKSVILhPSA
CancerH-2Db1333KVPRNQDWLgp100 (pmel17) 25-33
CancerH-2Db202CRMFPNAPYLWT-1 126-134 (Wilms tumor)
CancerH-2Db2675STHVNHLHCEndophilin-B2 244-252
CancerH-2Db2198VILTNPISMVEGFR2 400-408
CancerH-2Db2415YSSDNLYQMWilms Tumor protein (221- 229)
ChlamydiaH-2Db3943ASFVNPIYLCysteine-rich membrane protein 63-71
ChlamydiaH-2Db3947SAVSNLFYVPOMP 612-620
CMVH-2Db2313HGIRNASFIMCMV m45 985-993
HCVH-2Db791GAVQNEVTLHCV NS3 1629-1637
HIV/SIVH-2Db719AAVKNWMTQTLSIV gag
HPVH-2Db3404AGVDNRECIHPV L1 165-173
HPVH-2Db502HRAHYNIVTFHPV 16 E7 49-57
HSVH-2Db3405AAGPHNDMEIHSV p56 487-495
InfluenzaH-2Db9ASNENMDAMInfluenza A (NT60) NP 366-374
InfluenzaH-2Db119ASNENMETMInfluenza A (PR8) NP 366-374
InfluenzaH-2Db3410SCLENFRAYVInfluenza A polymerease PA 224-233
InfluenzaH-2Db120SSLENFRAYVInfluenza A (PR8) Polymerase acidic protein 224-233
LCMVH-2Db70FQPQNGQFILCMV NP 396-404
LCMVH-2Db69KAVYNFATCLCMV GP1 33-41
LCMVH-2Db142KAVYNFATMgp33 (C9M)
LCMVH-2Db186SGVENPGGYCLLCMV GP 276-286
MalariaH-2Db2697SQLLNAKYLPlasmodium berghei ANKA acid phosphatase 40-48
Minor Histocompatibility AntigenH-2Db328KCSRNRQYLmiHAg SMCY 738-746
Minor Histocompatibility AntigenH-2Db327WMHHNMDLImiHAg UTY 246-254
TuberculosisH-2Db547AIQGNVTSIMycobacterium tuberculosis ESAT-6 17-25
West NileH-2Db663LGMSNRDFLWest Nile Virus polyprotein 294-302
CMVH-2Dd278AGPPRYSRIMCMV m164 257-265
CMVH-2Dd2167LGPISGHVLpp65 15-23
HIV/SIVH-2Dd1684IGPGRAFYAHIV-1 US4 gp120 318-326
HIV/SIVH-2Dd177RGPGRAFVTIHIV-1 IIIB gp120 318-327
HSVH-2Dd3405BAGPHNDMEIHSV p56 487-495
CancerH-2Kb351HNTQYCNLMAGEA5 5-12
CancerH-2Kb3373SDYYFSWLmuFAP 289-296
CancerH-2Kb2754SIIVFNLLMC-38
CancerH-2Kb3376SKYVFENVMybpc2 295-302
CancerH-2Kb185SVYDFFVWLTyrosinase related protein-2 180-188
CancerH-2Kb2311TVSEFLKLMurine Survivin 97-104
CancerH-2Kb2585VGRNFTNLmTERT
CMVH-2Kb1915TVYGFCLLMCMV M139 419-426
COVID-19 / SARS-CoV-2H-2Kb4549SIIAYTMSLSARS-CoV-2 Spike glycoprotein 691-699
COVID-19 / SARS-CoV-2H-2Kb4544VVLSFELLSARS-CoV-2 Spike glycoprotein 505-523
HBVH-2Kb422ILSPFLPLLHBV surface antigen 208-216
HBVH-2Kb1431MGLKFRQLHBV core 93-100
HBVH-2Kb477VWLSVIWMHBV Surface antigen 190-197
HPVH-2Kb2560EVYDFAFRDLHPV E6 48-57
HSVH-2Kb188SSIEFARLHSV-1 gp B 498-505
LCMVH-2Kb2076ISHNFCNLLCMV GP 118-125
Model AntigensH-2Kb908KVVRFDKLOvalbumin (subdominant) 55-62
Model AntigensH-2Kb562LTFNYRNLHistocompatibility antigen 60 39-46
Model AntigensH-2Kb93SIINFEKLOvalbumin 257-264
Model AntigensH-2Kb1803SIYRYYGLSynthetic variant of VSV Nucleoprotein 498-505
MuLVH-2Kb828KSPWFTTLMuLV env 622-629 (MC38)
OtherH-2Kb2331TSINFVKIMHV 524-431
Sendai VirusH-2Kb56FAPGNYPALSendai virus NP 324-332
SV40H-2Kb488VVYDFLKLSV40 T antigen 404-411
Toxoplasma gondiiH-2Kb2156SVLAFRRLtgd057 57-64
Trypanosoma CruziH-2Kb708ANYNFTLVTrypanosoma cruzi SP 536-543
Trypanosoma CruziH-2Kb964VNHRFTLVTrypanosoma cruzi ASP-2 553-560
TuberculosisH-2Kb764IMYNYPAMMycobacterium tuberculosis TB10.4 4-11
TuberculosisH-2Kb769IMYNYPAMLMycobacterium tuberculosis TB10.4 4-12
VacciniaH-2Kb733TSYKFESVVaccinia virus WR epitope B8R 20-27
Vesicular Stomatitis VirusH-2Kb373RGYVYQGLVSV NP 52
Yellow Fever VirusH-2Kb1182ATLTYRMLYellow Fever Virus 17D polyprotein 268-275
CancerH-2Kd485AYIDFEMKISART3 315-323
CancerH-2Kd814EYILSLEELGPC3 298-306
CancerH-2Kd3381SYMLQALCITNPO3
CancerH-2Kd343TYVPANASLNeu/Her-2/Erbb2 proto-oncoprotein 66-74
CMVH-2Kd3412CYYASRTKLMCMV m145 451-459
HBVH-2Kd3916SYVNTNMGLCore 87-95
HBVH-2Kd529WYWGPSLYSIlarge envelope 362-371
HIV/SIVH-2Kd403AMQMLKDTIHIV gag p24 197-205
HIV/SIVH-2Kd176AMQMLKETIHIV-1 gag p24 199-207
HSVH-2Kd3407TYWPVVSDI207-215
InfluenzaH-2Kd240IYSTVASSLInfluenza A HA 533-541
InfluenzaH-2Kd98TYQRTRALVInfluenza A (PR8) NP 147-155
ListeriaH-2Kd178GYKDGNEYIListeria monocytogenes Listeriolysin 91-99
MalariaH-2Kd376SYIPSAEKIPlasmodium berghei CSP 252-260
MalariaH-2Kd2290SYVPSAEQIPlasmodium CSP
MalariaH-2Kd771YYIPHQSSLPlasmodium falciparum Liver stage antigen 1671-1679
Model AntigensH-2Kd198HYLSTQSALEnhanced Green Fluorescent Protein (eGFP) 200-208
OtherH-2Kd3414IYNVGQVSILeptospira
OtherH-2Kd458KYNKANVFLNRP-V7 superagonist peptide 8.3 Tg NOD mouse
OtherH-2Kd62RYLKNGKETLHLA-Cw3 170-179
RSVH-2Kd149KYKNAVTELRSV A strain F protein 85-93
RSVH-2Kd154SYIGSINNIRespiratory Syncytial Virus (RSV) M2 82-90
TuberculosisH-2Kd1263VYAGAMSGLMtb85A 145-152
AutoimmunityH-2Kd
580VYLKTNVFLIGRP (206-214)
CancerH-2Ld150LPYLGWLVFTumour Antigen P815 35-43
CMVH-2Ld21YPHFMPTNLMCMV IE1 168-176
HBVH-2Ld129IPQSLDSWWTSLHBV surface antigen 28-39
Model AntigensH-2Ld74TPHPARIGLE. coli beta-galactosidase 876-884
MuLVH-2Ld398SPSYVYHQFMuLV env gp70 423-431
TuberculosisH-2Ld158MPVGGQSSFMycobacterium tuberculosis Ag85A 70-78
Vesicular Stomatitis VirusH-2Ld622MPYLIDFGLVSV N 275-283
OtherH-2Ld
3051LPNWGKYVLRabies Glycoprotein (453-461)

Custom ProM1 Class I MHC Monomers – at no extra charge

Custom ProM1 Monomers for your allele/peptide of interest are available within approximately 6-7 weeks from ordering. Peptide sequences are subject to prior evaluation by ProImmune for binding. Once a peptide sequence is accepted for custom synthesis we will synthesize both the peptide and MHC monomer reagent. Custom ProM1™ Monomers are provided at no extra charge compared to catalog ProM1™ Monomers.

Available Alleles

HLA-A*01:01, A*02:01, A*03:01, A*11:01, A*24:02

HLA-B*07:02, B*08:01, B*35:01

HLA-E*01:01

H-2 Kb, Kd, Db, Ld

If your allele is not on the list above, please enquire.

Features of ProM1 Class I MHC Monomers

  • From the most experienced commercial providers of MHC multimers
  • Proven technology for detecting antigen-specific T cells
  • Broadest range of catalog items available
  • Flexible labelling options
  • Long-term storage
  • Industry leading customer service from immunologists who understand your work

Sample Product Sheets

ProM1 MHC Class I Monomer